UY27699A1 - Inhibidores. - Google Patents

Inhibidores.

Info

Publication number
UY27699A1
UY27699A1 UY27699A UY27699A UY27699A1 UY 27699 A1 UY27699 A1 UY 27699A1 UY 27699 A UY27699 A UY 27699A UY 27699 A UY27699 A UY 27699A UY 27699 A1 UY27699 A1 UY 27699A1
Authority
UY
Uruguay
Prior art keywords
lower alkyl
alkyl
optionally substituted
benzyl
phenyl
Prior art date
Application number
UY27699A
Other languages
English (en)
Inventor
David M Evans
Original Assignee
Ferreng B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferreng B V filed Critical Ferreng B V
Publication of UY27699A1 publication Critical patent/UY27699A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos de la fórmula general 1, o sales de los mismos aceptables para el uso farmacéutico, donde R1 se selecciona entre H, alquilo inferior, R4-CO, R4-O2CCH2, R5-OCO y R5-SO2; R2 se selecciona entre alquilo inferior, cicloalquilo, (C5-C12) cicioalquilalquilo opcionalmente sustituido con un grupo alquilo o alquiloxilo, aralquilo opcionalmente sustituido con hasta tres grupos seleccionados entre F, CI, Rr, I, OH, alquilo inferior, O-(alquilo inferior), O-bencilo, NH2, NO2, NH-acilo, CN y CF3, y aralquitoximetillo opcionalmente sustituido hasta tres grupos seleccionados entre F, CI, Br,OH, alquilo inferior y O-(alquilo inferior); o R1, y R2 son juntos un grupo seleccionado entre F, CI, Br, OH, alquilo inferior y O- (alquilo inferior); R3 se selecciona entre H, OH y O- alquilo inferior,R4 se selecciona entre H, alquilo inferior y fenilo; y R5 se selecciona entre alquilo inferior, fenilo y bencilo. Los compuestos son útiles como composiciones farmacéuticas.
UY27699A 2002-03-08 2003-03-06 Inhibidores. UY27699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0205527.5A GB0205527D0 (en) 2002-03-08 2002-03-08 Inhibitors

Publications (1)

Publication Number Publication Date
UY27699A1 true UY27699A1 (es) 2003-10-31

Family

ID=9932619

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27699A UY27699A1 (es) 2002-03-08 2003-03-06 Inhibidores.

Country Status (27)

Country Link
US (1) US7649000B2 (es)
EP (1) EP1483284B1 (es)
JP (1) JP4330450B2 (es)
KR (1) KR100974633B1 (es)
CN (1) CN1274713C (es)
AR (1) AR039868A1 (es)
AT (1) ATE333463T1 (es)
AU (1) AU2003208471B2 (es)
CA (1) CA2478099C (es)
DE (1) DE60306904T2 (es)
DK (1) DK1483284T3 (es)
EG (1) EG25482A (es)
ES (1) ES2264523T3 (es)
GB (1) GB0205527D0 (es)
HK (1) HK1072265A1 (es)
IL (2) IL163710A0 (es)
MX (1) MXPA04008523A (es)
MY (1) MY130830A (es)
NO (1) NO332678B1 (es)
NZ (1) NZ534891A (es)
PL (1) PL209670B1 (es)
PT (1) PT1483284E (es)
RU (1) RU2301225C2 (es)
TW (1) TWI283685B (es)
UY (1) UY27699A1 (es)
WO (1) WO2003076458A2 (es)
ZA (1) ZA200406856B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095327A1 (ja) 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
GB0918924D0 (en) * 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
EP2807157A1 (en) 2012-01-27 2014-12-03 Novartis AG 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013111107A1 (en) 2012-01-27 2013-08-01 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
HUE034829T2 (en) 2013-05-23 2018-03-28 Kalvista Pharmaceuticals Ltd Heterocyclic derivatives
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
RU2674028C2 (ru) 2013-08-14 2018-12-04 Калвиста Фармасьютикалз Лимитед Ингибиторы ферментов
RU2674604C2 (ru) * 2013-10-28 2018-12-11 БайсиклРД Лимитед Новые полипептиды
KR101927114B1 (ko) 2014-02-07 2018-12-10 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
IL293304A (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazole as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
HRP20220367T1 (hr) 2017-11-29 2022-05-27 Kalvista Pharmaceuticals Limited Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
EP4232031A1 (en) 2020-10-23 2023-08-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
US20240122909A1 (en) 2021-02-09 2024-04-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
EP4288036A1 (en) 2022-04-27 2023-12-13 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019558D0 (en) * 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
WO1993008211A1 (en) * 1991-10-23 1993-04-29 The Procter & Gamble Company Tripeptide derivative anti-inflammatory agents
SE9301911D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors

Also Published As

Publication number Publication date
GB0205527D0 (en) 2002-04-24
AU2003208471A1 (en) 2003-09-22
MXPA04008523A (es) 2004-12-06
IL163710A0 (en) 2005-12-18
HK1072265A1 (en) 2005-08-19
US7649000B2 (en) 2010-01-19
EP1483284B1 (en) 2006-07-19
WO2003076458A3 (en) 2003-11-06
NO332678B1 (no) 2012-12-03
CA2478099C (en) 2011-10-04
IL163710A (en) 2010-12-30
NO20043695L (no) 2004-10-07
JP4330450B2 (ja) 2009-09-16
RU2004126610A (ru) 2005-05-27
CA2478099A1 (en) 2003-09-18
PL209670B1 (pl) 2011-10-31
ZA200406856B (en) 2005-11-30
MY130830A (en) 2007-07-31
TWI283685B (en) 2007-07-11
PL372977A1 (en) 2005-08-08
KR20040089705A (ko) 2004-10-21
PT1483284E (pt) 2006-11-30
US20060052313A1 (en) 2006-03-09
CN1639186A (zh) 2005-07-13
JP2005533750A (ja) 2005-11-10
EG25482A (en) 2012-01-15
DE60306904T2 (de) 2007-02-08
WO2003076458A2 (en) 2003-09-18
NZ534891A (en) 2006-03-31
CN1274713C (zh) 2006-09-13
KR100974633B1 (ko) 2010-08-06
DK1483284T3 (da) 2006-10-16
RU2301225C2 (ru) 2007-06-20
AU2003208471B2 (en) 2006-09-28
TW200403255A (en) 2004-03-01
ES2264523T3 (es) 2007-01-01
ATE333463T1 (de) 2006-08-15
EP1483284A2 (en) 2004-12-08
AR039868A1 (es) 2005-03-09
DE60306904D1 (de) 2006-08-31

Similar Documents

Publication Publication Date Title
UY27699A1 (es) Inhibidores.
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
ATE338461T1 (de) Pyrazolpyrimidinfungizide
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
PE20040590A1 (es) Composiciones de pirrolotriazina anilina como inhibidores de cinasa
CO5261626A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialemente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologica
AR028914A1 (es) 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3
UY28565A1 (es) Nuevos compuestos
AR049883A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
GT200300010A (es) Esteres hidroxamato del acido n-(4-fenil sustituido)-antranilico
CO5690579A2 (es) Derivados de diarilcicloalquilo, metodo para su produccion y su uso como medicamentos
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
UY27853A1 (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
AR049023A1 (es) Imidazoles como inihibidores de la hmg-coa reductasa
CR9499A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
IL173895A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
AR053560A1 (es) Compuestos antibacterianos de 3,3' dialcoxi-2,2' -dihidroxi -1,1' -bifenilo 5,5' disustituidos y metodos relacionados
SV2002000296A (es) Compuestos quimicos caso ppd 50479/sv
EA200501164A1 (ru) Индазоламиды с аналгетической активностью

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150413